Wednesday, July 7, 2021

Slaoui apologizes ‘unreservedly’ after sexual harassment allegations prompt biotechs to part ways


No deflecting, no denying. Moncef Slaoui, M.D., issued an open apology around the sexual harassment allegation that led GlaxoSmithKline to cut ties on Wednesday. But the biopharma world isn’t in a forgiving mood right now.

“I would like to apologize unreservedly to the employee concerned and I am deeply sorry for any distress caused,” Slaoui said in a statement Wednesday.

The former GSK vaccine exec and head of Operation Warp Speed said he’ll “work hard to redeem” himself with those affected, but for now he’ll hunker down by stepping away from his current positions in the industry to focus on family.

The apology came after GSK booted him from chairmanship at GSK-controlled Galvani Bioelectronics over allegations of harassment and inappropriate behavior by an employee that happened years ago, when he was with GSK. The British drugmaker said an investigation into Slaoui’s conduct had substantiated the claims.

Whatever his own decisions, GSK’s damning accusation Wednesday leaves little room for Slaoui’s career in today’s biopharma indutstry. Newly launched mega-biotech Centessa Pharmaceuticals immediately parted ways with him, merely a month after tapping him as chief scientific officer.

RELATED: GSK cuts ties with Slaoui over sexual harassment allegations as CEO Walmsley vows to rename R&D site

Centessa’s management and board “were troubled to learn of yesterday’s news regarding Dr. Slaoui,” Centessa CEO Saurabh Saha, M.D., Ph.D., said in a statement Thursday. “Centessa is absolutely committed to fostering a culture of respect that is free from harassment and discrimination of any kind.”

Centessa was founded by life sciences venture capital bigwig Medicxi, where Slaoui has been a partner since September 2017. As of Thursday morning, Saloui’s intro can still be seen on Medicxi’s website, and the company didn’t immediately reply to a request for comment. By way of the European investment shop, Slaoui also holds board positions at other Medicxi portfolio companies such as U.K. biotech Divide & Conquer.

RELATED: Warp Speed chief Slaoui resigns at Biden’s request as COVID-19 shots are unleashed: report

U.S. vaccine developer Vaxcyte said Thursday that Slaoui has stepped down as its chairman. Medixci also participated in the company’s previous funding round when the firm was known as SutroVax.



Source link

Stay Connected

1,605FansLike
11,000FollowersFollow
342FollowersFollow
775FollowersFollow

Latest Articles

Covid’s second wave proves lethal for pregnant women

At SVP Hospital in Ahmedabad – one of the major Covid-19 hospitals of the city – 148 pregnant women with Covid-19 infection were admitted...

7 Tips to Keep Your Gut Healthy

This is common to say health (and illness) starts in your gut. If you have poor gut health, you’ll experience anything from wrinkled skin, to...

SII making first batch of Covovax: Poonawalla

The first batch of Covovax, a Covid-19 vaccine developed by Novavax Inc, is being manufactured at the Serum Institute of India's Pune facility, SII...

Sputnik V is safest among all Covid-19 vaccines, no deaths recorded: Buenos Aires study

A study by the Buenos Aires Ministry of Health to monitor the safety of the Sputnik V vaccine against Covid-19 confirmed on Thursday that...

Telangana caps Covid treatment charges in private hospitals

Hyderabad: The government of Telangana on Wednesday issued orders fixing treatment and investigation charges for Covid-19 in private hospitals.The state government, which had capped...